Abstract 307P
Background
The incident rate of thyroid nodules has risen globally, thus it is critical to identify malignancy among benign lesions. Currently available molecular diagnostics for malignant nodules have not achieved the desired degree of accuracy. We aimed to identify DNA methylation markers to accurately classify benign and malignant nodules, and to develop tools for non-invasive screening of thyroid cancer.
Methods
Marker screening was performed on papillary thyroid cancer (PTC, 37 tissues, 55 plasmas), benign nodules (BTN, 37 tissues, 55 plasmas) and normal samples (20 buffy coats; 123 plasmas) by MONOD+ assay. We identified differential markers by Wilcox rank sum test using Benjamini-Hochberg procedure to control false discovery rate. Predication models were built using machine-learning algorithms including random forest and support vector machine. They were validated using public DNA methylation data of thyroid tissues. Candidate markers were developed into a targeted sequencing panel and were validated on plasma DNA samples (115 PTC, 102 BTN). Best-performing markers were developed into an improved panel to classify additional plasma DNA samples of malignant or benign thyroid nodules.
Results
From the MONOD+ data we identified over 1000 DNA methylation markers significantly differential between malignant and benign nodules. We built a classification model by random forest method, which classified DNA methylation profiles of thyroid nodules at a sensitivity of 90.5% and a specificity of 91.9% (95% CI, 0.91-1.0). We produced a targeted sequencing panel using those markers and sequenced plasma DNA of PTC and benign nodules. Two thirds of them were used as a training cohort to build a prediction model, which classified the remaining samples at an accuracy of 72%. We selected the best-performing markers to build an advanced version of panel, which classified additional over 500 plasma DNA samples of thyroid nodules with increased sequencing depth to improve the accuracy and consistency in classification.
Conclusions
Our study demonstrates that DNA methylation markers can robustly differentiate thyroid nodules based on their malignancy. They are thus promising candidates to develop non-invasive diagnostics for thyroid cancer screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The First Affiliated Hospital, Sun Yat-sen University.
Funding
The First Affiliated Hospital, Sun Yat-sen University.
Disclosure
Z. Su, Q. He: Shareholder/Stockholder/Stock options, Full/Part-time employment: Singlera Genomics. L. Cheng: Full/Part-time employment: Singlera Genomics. R. Liu: Leadership role, Shareholder/Stockholder/Stock options, Full/Part-time employment: Singlera Genomics. All other authors have declared no conflicts of interest.
Resources from the same session
94P - Prognostic influence of mean platelet volume on stage III rectal cancer patients: A tertiary cancer center study
Presenter: Pavan Jonnada
Session: e-Poster Display Session
95P - Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer
Presenter: Tatsuki Ikoma
Session: e-Poster Display Session
96P - Early-onset colorectal cancer prognosis, conflict resolution, review of literature and meta-analysis
Presenter: Ereny Poles
Session: e-Poster Display Session
97P - A population-based study to assess the associations of rural residence and low socioeconomic status (SES) with cardiovascular disease (CVD) in patients with colorectal cancer (CRC)
Presenter: Atul Batra
Session: e-Poster Display Session
98P - Operational challenges of an Asian Pacific (APAC) academic oncology clinical trial
Presenter: Daphne Day
Session: e-Poster Display Session
99P - Development of a qRT-PCR-based diagnostic test to identify colorectal cancer patients with recurrent R-Spondin gene fusions
Presenter: Veronica Diermayr
Session: e-Poster Display Session
100P - Individualized treatment of advanced digestive system tumour guided by PDTX mouse model: A multicenter trial
Presenter: yuan cheng
Session: e-Poster Display Session
101P - HIF1-α depletion overcomes resistance to oxaliplatin in colorectal cancer via ERK signalling pathway
Presenter: Se Jun Park
Session: e-Poster Display Session
102P - Colorectal cancer organoids culture exploits new neoadjuvant therapy resistance mechanisms and therapeutic targets
Presenter: Yun Deng
Session: e-Poster Display Session
103P - Comprehensive genomic landscape in younger and older Chinese patients with colorectal cancer
Presenter: Huina Wang
Session: e-Poster Display Session